CDK4/6抑制剂联合放疗在激素受体阳性/HER2阴性乳腺癌患者中的安全性与可行性:系统综述与Meta分析
该系统综述与Meta分析纳入15项研究共1133例激素受体阳性/HER2阴性乳腺癌患者,其中617例接受CDK4/6抑制剂联合放疗,中位随访17.0个月。汇总严重血液学毒性发生率为29.4%,严重非血液学毒性为2.8%,CDK4/6抑制剂减量率为24.0%,因毒性停药率为2.3%。作者认为放疗联合CDK4/6抑制剂治疗总体安全且耐受良好,仍为可行的治疗选择。
要点
- CDK4/6抑制剂联合放疗的严重血液学毒性汇总发生率为29.4%(95%CI 14.0%-47.4%)。
- 严重非血液学毒性汇总发生率为2.8%(95%CI 1.1%-4.8%),因毒性停药率为2.3%(95%CI 0.4%-5.2%)。
- CDK4/6抑制剂减量率在联合放疗组与单用CDK4/6抑制剂组间无显著差异(OR 0.934,95%CI 0.66-1.33)。
核心结论
- 作者认为,在乳腺癌患者中,CDK4/6抑制剂治疗基础上加用放疗总体安全且耐受良好,仍为可行的治疗选择。
研究设计与样本
- 系统综述与Meta分析,检索PubMed/MEDLINE、Web of Science和Scopus,纳入15项研究共1133例激素受体阳性/HER2阴性晚期或转移性乳腺癌患者,其中617例接受CDK4/6抑制剂联合放疗,中位随访17.0个月(IQR 9.2-18.0),中位年龄58.8岁(IQR 55.5-62.5)。
主要发现
- 严重血液学毒性汇总发生率为29.4%(95%CI 14.0%-47.4%;I²=93%;τ²=0.084;p<0.01)。
- 严重非血液学毒性汇总发生率为2.8%(95%CI 1.1%-4.8%;I²=0%;τ²=0.0;p=0.67)。
- CDK4/6抑制剂减量汇总发生率为24.0%(95%CI 11.1%-39.4%;I²=90%;τ²=0.052;p<0.01),联合放疗组与单用CDK4/6抑制剂组间无差异(OR 0.934;95%CI 0.66-1.33;I²=0%;τ²=0.0;p=0.56)。
- 因毒性停用CDK4/6抑制剂的汇总发生率为2.3%(95%CI 0.4%-5.2%;I²=23%;τ²=0.002;p=0.24)。
临床怎么用
- 作者认为,对于激素受体阳性/HER2阴性乳腺癌患者,CDK4/6抑制剂联合放疗总体安全且耐受良好,仍为可行的治疗选择。
局限性
- 严重血液学毒性汇总发生率存在高度异质性(I²=93%)。
- CDK4/6抑制剂减量汇总发生率存在高度异质性(I²=90%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The addition of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy in hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2-) breast cancer has led to practice-changing improvements in overall survival. However, there are conflicting data concerning the safety of CDK4/6i combination with radiotherapy, and no consensus guidelines exist to guide practice. We conducted a meta-analysis to assess the safety and feasibility of CDK4/6i treatment with radiotherapy. MATERIALS AND METHODS: A comprehensive search was performed in PubMed/MEDLINE, Web of Science, and Scopus, for studies in advanced/metastatic breast cancer receiving CDK4/6i and radiotherapy with the provided safety data on the occurrence of toxicity. The main outcomes were safety (grade 3-5 adverse events), CDK 4/6i dose reduction, and the discontinuation rate due to toxicity. RESULTS: Fifteen studies comprising 1133 patients with HR+/HER2- breast cancer patients were included. Among them, 617 pts received CDK4/6i and radiotherapy; the median follow-up was 17.0 months (IQR 9.2 - 18.0), and the median age was 58.8 years (IQR 55.5---62.5). The pooled prevalence of severe hematologic toxicity was 29.4% (95% CI 14.0% - 47.4%; I2 = 93%; τ2 = 0.084; p < 0.01 and severe non-hematologic toxicity was 2.8% (95% CI 1.1% - 4.8%; I2 = 0%; τ2 = 0.0; p = 0.67). The pooled prevalence of CDK4/6i dose reduction was 24.0% (95% CI 11.1% - 39.4%; I2 = 90%; τ2 = 0.052; p < 0.01) with no difference between CDK4/6i plus RT vs. CDK4/6i (odds ratio of 0.934; 95% CI 0.66 - 1.33; I2 = 0%; τ2 = 0.0; p = 0.56). The pooled prevalence of CDK4/6i discontinuation due to toxicity was 2.3% (95% CI 0.4% - 5.2%; I2 = 23%; τ2 = 0.002; p = 0.24). CONCLUSION: The findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option.
引用
- Kubeczko M, Jarząb M, Gabryś D, et al. Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis. Radiother Oncol. 2023. PMID: 37536378. doi:10.1016/j.radonc.2023.109839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。